{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}],"units":"Participants"}],"description":"CR Rate is defined as the percentage of participants with CR.","groups":[{"description":"This substudy was withdrawn; therefore, no participants were enrolled.","id":"OG000","title":"Substudy A (Relapsed/Refractory Waldenstrom Macroglobulinemia): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Richter Transformation received the following treatment during the study. Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG001","title":"Substudy B (Relapsed/Refractory Richter Transformation): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory Burkitt Lymphoma received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG002","title":"Substudy C (Relapsed/Refractory Burkitt Lymphoma): Brexucabtagene Autoleucel"},{"description":"Participants with Relapsed/Refractory hairy cell leukemia received the following treatment during the study: Lymphodepletion chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3). A single IV infusion of brexucabtagene autoleucel at target dose of 2 × 10\\^6 anti-CD19 CAR T cells/kg on Day 0.","id":"OG003","title":"Substudy D (Relapsed/Refractory Hairy Cell Leukemia): Brexucabtagene Autoleucel"}],"populationDescription":"Data cannot be reported for this outcome measure because all substudies were terminated before the central committee could be formed hence central assessment was not performed. There are no plans to analyze these data in the future.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"All Substudies (Substudies A, B, C and D): Complete Response (CR) Rate Determined by Central Assessment","type":"SECONDARY"}